Cited by 388Sexual function and dysfunction studiesTreatment of Major DepressionSchizophrenia research and treatment

Antidepressant-Induced Sexual Dysfunction

Gregorian, Razmic S, Golden, Katharine A, Bahce, Asena, Goodman, Clifford, Kwong, W Jacqueline, Khan, Zeba M·2002·Annals of Pharmacotherapy

Abstract

OBJECTIVE: To review the evidence regarding antidepressant-induced sexual dysfunction and address implications for treatment strategy and health plan coverage policies for antidepressant medications. DATA SOURCES: Primary articles were identified by a MEDLINE and HealthSTAR search to identify English-language studies published between January 1986 and July 2000. Search terms included sexual dysfunction or sexual function and antidepressants, fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram, venlafaxine, nefazodone, bupropion, and mirtazapine. A cross-check of references cited in 10 published reviews yielded additional in-scope articles. STUDY SELECTION AND DATA EXTRACTION: Approximately 200 articles were identified, including 8 randomized controlled trials and numerous open-label studies, case series, and case reports. Of the randomized controlled trials, only 5 were designed to evaluate the incidence of sexual dysfunction associated with antidepressant treatment. Three additional randomized controlled trials included a structured assessment of sexual dysfunction within an efficacy trial. Data extraction excluded case reports, letters, and other limited study designs. A panel survey augmented published reports. DATA SYNTHESIS: Sexual dysfunction is a relatively common adverse effect of many of the antidepressants in common use today. Rates of sexual dysfunction observed in clinical practice may be higher than those reported in the product information for several agents. Selective serotonin-reuptake inhibitors (SSRIs) appear to be the class of antidepressants most likely to cause sexual dysfunction. Published studies suggest that between 30% and 60% of SSRI-treated patients may experience some form of treatment-induced sexual dysfunction. Bupropion and nefazodone appear to be much less likely to cause sexual dysfunction (≤10% of patients). Mirtazapine also appears to be associated with a low rate of sexual adverse effects. Panel results largely reflect the consensus of the literature. CONCLUSIONS: Sexual dysfunction is a common adverse effect of antidepressant treatment. Physicians should monitor their patients for antidepressant-induced sexual adverse effects, as these may affect compliance with therapy and ultimate treatment success. In addition to the consequences for patient health and well-being, managed-care organizations should be concerned with sexually related adverse effects of antidepressants, insofar as additional healthcare resources may be required to treat depressed patients in whom these adverse effects arise.

Integrity signals

Registry

Crossref · 10.1345/aph.1a195

Cites

193 of 193 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M.
Affiliations
  • Lewin Group (United States) (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • GlaxoSmithKline (United States) (US)
  • GlaxoSmithKline (United Kingdom) (GB)
Corresponding author
Goodman, Clifford
Venue
Annals of Pharmacotherapy
Published
2002-10
Volume
36
Issue
10
Pages
1577-1589
ISSN
  • 0012-6578 (ISSN-L)
  • 1060-0280
  • 1542-6270
OpenAlex
W2171466849
Cited by
320
References
71
Citations by year
2026: 3 · 2025: 5 · 2024: 11 · 2023: 9 · 2022: 18 · 2021: 4 · 2020: 9 · 2019: 10 · 2018: 15 · 2017: 6 · 2016: 12 · 2015: 13 · 2014: 17 · 2013: 22 · 2012: 22
FWCI
7.68
Type
journal article
Language
en
Open access
closed
Locations
  • Annals of Pharmacotherapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
antidepressant-induced sexual dysfunction, selective serotonin reuptake inhibitors, adverse drug reactions, fluoxetine, sertraline, paroxetine, bupropion, nefazodone, mirtazapine, depression treatment, medication adherence
MeSH terms
Antidepressive Agents, Clinical Trials as Topic, Depressive Disorder, Female, Humans, Libido, Male, Selective Serotonin Reuptake Inhibitors, Sexual Dysfunctions, Psychological

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review